## LH: Labcorp Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.2% below STRENGTH zone (4.0-10.0%); PEG 1.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($244.64)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. LH SEC Filings - Labcorp Holdings Inc 10-K, 10-Q, 8-K Forms**
- Source: Stock Titan | 20251225T020829 | Neutral | Relevance: 100%
- This article provides investors with a dedicated resource for Labcorp Holdings (LH) SEC filings, including annual, quarterly, material events, and insider trading reports. Stock Titan offers AI-powered summaries and real-time alerts for these documents, aiming to simplify the process of tracking crucial company information. It highlights recent insider trading activity where LH's Chief Accounting Officer sold approximately $52.7k in shares.

**2. Voya Investment Management LLC Sells 5,531 Shares of Labcorp Holdings Inc. $LH**
- Source: MarketBeat | 20251225T130623 | Somewhat-Bullish | Relevance: 99%
- Voya Investment Management LLC reduced its stake in Labcorp Holdings Inc. by 22.5% in the third quarter, selling 5,531 shares to hold 19,103 shares valued at approximately $5.484 million. Despite this, Labcorp has received a "Moderate Buy" consensus rating from analysts, with multiple firms raising price targets, and the company reported strong Q3 earnings exceeding estimates and offering optimistic FY2025 guidance.

**3. Guardant Health (GH): Reassessing Valuation After New Trial Library Partnership and Strong Share Price Gains**
- Source: Simply Wall Street | 20251226T030926 | Neutral | Relevance: 63%
- Guardant Health (GH) recently partnered with Trial Library, aiming to streamline cancer clinical trial enrollment, particularly in community clinics. This collaboration follows a period of significant share price appreciation for GH, with a 70% return over three months and over 220% year-to-date. While a narrative valuation suggests the stock is undervalued at $102.38 against a fair value of $111.82, a sales-based valuation indicates Guardant trades at a premium compared to its peers, raising questions about whether the current price fully incorporates future growth expectations.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($3.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.7%)
- Blackrock Inc.: 9.8% (-10.3%)
- State Street Corpora: 4.6% (-0.8%)
- Victory Capital Mana: 3.2% (+20.0%)
- JPMORGAN CHASE & CO: 2.6% (+64.8%)

### Key Risks

1. Insider selling cluster: $3.4M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.86 elevated, pricing in significant growth expectations. Insider selling cluster ($3.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $21.1B |
| Beta | 0.96 |
| 52W Range | $209.38 - $293.72 |
| Short Interest | 5.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.86 |
| Forward P/E | 14.5 |
| Current P/E | 15.5 |
| YoY Growth | 7.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -4.2% to -3.2% (+1.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 7.2pp (needs >4.0% for momentum thesis). Underperforming sector by 3.7pp, stock-specific weakness. Below SMA200 (0.98x), long-term trend not supportive. MACD histogram bearish (-0.57), momentum weakening. RSI neutral at 40. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.17% (CS: 18) | Weak |
| RSI_14 | 40.3 | Neutral |
| MACD Histogram | -0.57 | Bearish |
| vs SMA20 | 0.977x | Below |
| vs SMA50 | 0.963x | Below |
| vs SMA200 | 0.985x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $253.86
- **Stop Loss:** $244.64 (3.6% risk)
- **Target:** $263.08 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 143
- **Position Value:** $36,301.98
- **Portfolio %:** 36.30%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-05 (Est: $3.94)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.14 | $4.18 | +1.0% |
| 2025Q2 | $4.18 | $4.35 | +4.1% |
| 2025Q1 | $3.73 | $3.84 | +2.8% |
| 2024Q4 | $3.39 | $3.45 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*